TRexBio

TRexBio is a private, preclinical-to-clinical stage biotech leveraging human tissue biology to develop novel Treg-targeting therapeutics for immune-mediated diseases. The company's core asset is its Deep Biology Platform, which analyzes human tissue samples across health and disease states to map immune dysregulation and identify actionable targets. Its lead candidate, TRB-061, a TNFR2 agonist, is in clinical development for atopic dermatitis, with a broader pipeline aimed at dermatology and gastroenterology. The company is backed by a strong team and investor syndicate, positioning it to pursue durable, disease-modifying treatments in large inflammatory disease markets.

Deep Biology Platform that decodes regulatory T cell (Treg) behavior in human tissues using modern sequencing, computational tools, and disease-relevant human assay systems to identify novel therapeutic targets for immune-mediated diseases.

TRexBio competes in the crowded immunology space against large pharma and biotechs developing various anti-inflammatory biologics and small molecules. Its differentiation lies in its tissue-centric, Treg-focused approach, competing with other companies exploring Treg therapies (e.g., via IL-2, TNFR2) but with a unique discovery platform rooted in deep human tissue biology.